American College of Cardiology 2010

Late-Breaking Clinical Trials I
Domingo, 14 de março de 2010, 8:00 - 9:20


3010-6: Effects of combination lipid therapy on cardiovascular events in type 2 diabetes mellitus: The ACCORD lipid study
Henry Ginsberg, Columbia University College of Physicians & Surgeons, New York, NY

3010-8: Effects of intensive blood pressure control on cardiovascular events in type 2 diabetes mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) blood pressure trial
William C Cushman, Veterans Affairs Medical Center, Memphis, TN

3010-10: Rethinking lower BP goals for diabetics with documented coronary artery disease: Findings from the International Verapamil SR-Trandolapril Study (INVEST)
Rhonda M Cooper-Dehoff, University of Florida, Gainesville

3010-12: The Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial
Robert M Califf, Duke Clinical Research Institute, Durham, NC

3010-14: Primary safety and efficacy end points of the EVEREST II randomized clinical trial
Ted Feldman, Evanston Hospital, IL


Late-Breaking Clinical Trials II
Segunda-Feira, 15 de março de 2010, 8:00 - 9:20


3015-6: Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: First results of the North American Arctic Front STOP-AF clinical trial
Douglas L Packer, Mayo Clinic, Rochester, MN

3015-8: Rate-control efficacy in permanent atrial fibrillation: A comparison between lenient vs strict rate control in patients with and without heart failure. The RACE II study
Isabelle C Van Gelder, University Medical Center Groningen, the Netherlands

3015-10: The impact of remote monitoring with automatic clinician notifications on the clinical care of ICD and CRT-D patients
George H Crossley III, St Thomas Research Institute, Nashville, TN

3015-12: A randomized clinical trial of three doses of a long-acting oral direct factor Xa inhibitor (betrixaban) in patients with atrial fibrillation
Michael D Ezekowitz, Lankenau Institute for Medical Research, Wynnewood, PA

3015-14: Catheter Ablation vs Antiarrhythmic Drug Therapy for Atrial Fibrillation: First results of the CABANA pilot study
Douglas L Packer, Mayo Clinic, Rochester, MN


Late-Breaking Clinical Trials III
Segunda-Feira, 15 de março de 2010, 10:30 - 11:52


3016-06: Randomized all-comer comparison of zotarolimus-eluting and sirolimuseluting coronary stents: 18-month follow-up in the SORT OUT III trial
Michael Maeng, Aarhus University Hospital, Denmark

3016-08: Randomized trial of a polymer-free dual drug-eluting stent vs polymer-based Cypher and Endeavor drug-eluting stents: Two-year clinical and angiographic outcomes
Robert A Byrne, Deutsches Herzzentrum, Munich, Germany

3016-10: First report of the PERSEUS randomized controlled trial comparison of a novel platinum-chromium, thin-strut TAXUS Element stent vs the TAXUS Express stent in de novo coronary stenoses
Dean J Kereiakes, Christ Hospital Heart and Vascular Center/Lindner Center for Research and Education, Cincinnati, OH

3016-12: Randomized trial evaluating the efficacy of cilostazol on ischemic vascular complications after drug-eluting stent implantation for coronary heart disease: Influence of Cilostazol-Based Triple Antiplatelet Therapy on Ischemic Complication After Drug-Eluting Stent Implantation (CILON-T) study
Hyo-Soo Kim, Seoul National University Hospital, South Korea

3016-14: Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: A randomized, multicenter trial
Seung-Jung Park, Asan Medical Center, Seoul, South Korea


Late-Breaking Clinical Trials IV
Terça-Feira, 16 de Março de 2010, 8:00 - 9:20


3019-6: Effect of genotyping warfarin patients on outcomes: Results from the National Community-based Medco-Mayo Warfarin Effectiveness Study (MM-WES)
Robert S Epstein, Medco Health Solution, Franklin Lakes, NJ

3019-8: The Diuretic Optimization Strategies Evaluation (DOSE) study: A randomized, double blind, placebo-controlled trial of diuretic strategies in acute decompensated heart failure
Gary Michael Felker, Duke University School of Medicine, Durham, NC

3019-10: Effect of the direct renin inhibitor aliskiren on left ventricular remodeling following myocardial infarction with left ventricular dysfunction: ASPIRE
Scott D Solomon, Brigham and Women’s Hospital, Boston, MA

3019-12: Effects of clinical characteristics and treatments on gender difference in outcomes after acute myocardial infarction: A propensity score-matched analysis
François Schiele, University Hospital Jean Minjoz, Besançon, France

3019-14: Influence of reduction of left ventricular volume on outcome after coronary artery bypass grafting with or without surgical ventricular reconstruction
Robert E Michler, Duke Clinical Research Institute, Durham, NC


Late-Breaking Clinical Trials V
Terça-Feira, 16 de Março de 2010, 10:30 - 11:51


3020-06: Randomized comparison of Angiojet rheolytic thrombectomy before direct infarct artery stenting to direct stenting alone in patients with acute myocardial infarction: the Jetstent trial
David Antoniucci, Careggi Hospital, Florence, Italy

3020-08: Long-term outcome after drug-eluting vs bare-metal stent implantation in patients with ST-elevation myocardial infarction. Three-year follow-up of the DEDICATION trial
Peter Clemmensen, Copenhagen University Hospital, Denmark

3020-09: Five-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent vs a bare-metal stent in acute ST-segment elevation myocardial infarction. A follow-up study of the PASSION trial
Maarten Vink, Onze Lieve Vrouwe Gasthuis, Amsterdam, the Netherlands

3020-11: Ticagrelor vs clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the PLATO trial
Claes Held, Uppsala Clinical Research Center, Sweden

3020-13: A randomized trial of radial artery grafts vs saphenous vein grafts in coronary artery bypass surgery: VA Cooperative Study
Steven Goldman, Southern Arizona VA Health Care System, Tucson